secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vera Therapeutics, Inc. (VERA)
CIK:        0001831828
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001193125-25-265799
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vera Therapeutics Q3 net loss $80.3M; atacicept BLA submission on track for Q4 2025
--------------------------------------------------------------------------------

- Net loss $80.3M ($1.26/sh) vs $46.6M ($0.85) in Q3 2024; cash & securities $497.4M.
- BLA for atacicept in IgA nephropathy under Accelerated Approval submitted to FDA expected Q4 2025.
- ORIGIN 3 36-week results presented as late-breaking oral at ASN Kidney Week on Nov 6, 2025.
- PIONEER basket trial and ORIGIN Extend study actively enrolling; initial PIONEER data expected Q4 2025.
- Potential FDA approval and U.S. commercial launch of atacicept anticipated in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831828/000119312525265799/0001193125-25-265799-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831828/000119312525265799/vera-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-265799

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer